Zhuhai Trinomab Pharmaceutical Co., Ltd. Class A
SSSE:68880622.35
CNY
-1.13
(-4.81%)
ISIN
CNE100007WN7
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Wei Hong Zheng
- Full Time Employees
- 843
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Zhuhai China
- IPO Date
- Jul 21, 2026
- Website
- trinomab.com
- Similar Companies
- Business
- Zhuhai Trinomab Pharmaceutical Co., Ltd. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes native, fully human monoclonal antibody therapeutics and biological medicines. The company leverages its proprietary fourth-generation antibody discovery platform, known as HitmAb, to directly isolate native human antibodies from single human memory B cells for applications in infectious diseases, autoimmune disorders, and oncology. Its core pipeline and product offerings comprise TNM002, a fully human monoclonal antibody targeting tetanus toxin for post-exposure prophylaxis and prevention; TNM001, a long-acting recombinant monoclonal antibody targeting the respiratory syncytial virus (RSV) F protein for the prevention of lower respiratory tract infections in infants; TNM009, a recombinant fully human anti-rabies monoclonal antibody cocktail for post-exposure rabies prophylaxis; TNM005, a therapeutic antibody targeting varicella-zoster virus (VZV) infections; TNM006, a monoclonal antibody for human cytomegalovirus (HCMV) prevention and treatment; and multiple early-stage antibody programs directed at malignant tumors and inflammatory conditions. In addition to therapeutic drug development, the company offers antibody platform discovery services, technical licensing, and translational research capabilities. Founded in 2015, Zhuhai Trinomab Pharmaceutical Co., Ltd. is headquartered in Zhuhai, Guangdong Province, China, with Class A ordinary shares listed on the Shanghai Stock Exchange under the ticker 688806. The company serves public health systems, hospital networks, immunization clinics, and commercial biopharmaceutical partners across Greater China and global target markets. In recent developments, Zhuhai Trinomab Pharmaceutical Co., Ltd. has advanced its clinical and commercial transition by submitting a New Drug Application and Biologics License Application to the National Medical Products Administration (NMPA) of China for its flagship tetanus antibody TNM002 following the successful completion of pivotal Phase III trials. The company has also progressed its pediatric RSV candidate TNM001 into late-stage clinical evaluation and advanced clinical trials for rabies candidate TNM009 and VZV candidate TNM005. To support near-term commercial launches, the company has completed construction and operational validation of its commercial-scale biomanufacturing facility compliant with international Good Manufacturing Practice (GMP) standards at the Zhuhai International Health Port. Furthermore, the company has completed public capital market integration on the STAR Market and formed strategic commercialization and distribution partnerships with pharmaceutical distributors to establish national market access and supply chain infrastructure for its upcoming biological products.